On their Top-line Data (two first bullet items in PR):
- The median change in 28-day seizure frequency from baseline in the ITT (intent-to-treat) population (primary endpoint) was a decrease of 43% (n=7). - The median change from baseline in seizure-free days in the ITT population (key secondary endpoint) was an increase of 78% (n=5; two subjects cannot be calculated due to 0 baseline seizure-free days).
The sample size is too small n=7 and they play fast and loose with the ITT (switching from n=7 in 1st bullet item to n=5 in 2nd bullet).
On the other hand Ecor1 acquired 12.2% MRNS (reported 8/8/17 in Edgar) Deerfield acquired 9.98% MRNS (reported 7/17/17 in Edgar)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.